CLINICAL TRIALS PROFILE FOR ATIPRIMOD
✉ Email this page to a colleague
Clinical Trials for Atiprimod
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00086216 ↗ | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | Completed | Callisto Pharmaceuticals | Phase 1/Phase 2 | This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma. |
| NCT00214838 ↗ | An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer | Unknown status | Callisto Pharmaceuticals | Phase 1/Phase 2 | The primary objectives of this study are to identify the maximum tolerated dose and to evaluate safety of atiprimod in patients with advanced cancer. |
| NCT00388063 ↗ | Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | Completed | Callisto Pharmaceuticals | Phase 2 | This study will evaluate the safety and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable local-regional cancer and who have either symptoms (diarrhea, flushing and/or wheezing) despite standard therapy (octreotide) or progression of neuroendocrine tumor(s). |
| NCT00430014 ↗ | Study of Atiprimod Treatment for Patients With Advanced Cancer | Terminated | Callisto Pharmaceuticals | Phase 1 | Primary Objectives: The primary objectives of this study are to identify the maximum tolerated dose (MTD) and to evaluate the safety of atiprimod when given in doses starting at 60 mg/day and ranging to 360 mg/day, or the MTD, whichever is lower, in patients with advanced cancer. Secondary Objectives: The secondary objectives of this study are to measure the pharmacokinetics of atiprimod and to evaluate the efficacy of atiprimod treatment in patients with advanced cancer, and to compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose, with the intent of switching to capsules for the dose escalation if the capsules pose no safety issues. |
| NCT00430014 ↗ | Study of Atiprimod Treatment for Patients With Advanced Cancer | Terminated | M.D. Anderson Cancer Center | Phase 1 | Primary Objectives: The primary objectives of this study are to identify the maximum tolerated dose (MTD) and to evaluate the safety of atiprimod when given in doses starting at 60 mg/day and ranging to 360 mg/day, or the MTD, whichever is lower, in patients with advanced cancer. Secondary Objectives: The secondary objectives of this study are to measure the pharmacokinetics of atiprimod and to evaluate the efficacy of atiprimod treatment in patients with advanced cancer, and to compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose, with the intent of switching to capsules for the dose escalation if the capsules pose no safety issues. |
| NCT00663429 ↗ | Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma | Completed | Callisto Pharmaceuticals | Phase 2 | This study is an extension study to the Callisto protocol CP-106. Subjects must have completed all 12 treatment cycles of CP-106 without disease progression as per RECIST criteria,to be eligible to to be enrolled in this study. This study will evaluate the safety and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable local-regional cancer and who have either symptoms (diarrhea, flushing and/or wheezing) despite standard therapy (octreotide) or progression of neuroendocrine tumor(s). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Atiprimod
Condition Name
Clinical Trial Locations for Atiprimod
Trials by Country
Clinical Trial Progress for Atiprimod
Clinical Trial Phase
Clinical Trial Sponsors for Atiprimod
Sponsor Name
